Analysts are mixed as to whether clearance will be granted. And whichever way the FDA goes, the impact on Biogen’s stock could be huge, they say.
This is “the mother of all binary events,” said J.P. Morgan Chase analyst Cory Kasimov, according to Bloomberg. A rejection could depress Biogen shares to $200, while approval could boost them to $450, he said.
Biogen recently traded at $287.75, up 5.6%. It has climbed 15% in the past six months.
Clearance would make aducanumab the first authorized treatment for the memory-destroying disease, Reuters reports. Alzheimer’s represents the sixth most prevalent cause of death in the U.S.
It also could have an impact on other neurological drugs and the pharmaceutical industry as a whole, the news service said.
In January, analysts reacted positively to the FDA’s decision to extend by three months the review period for aducanumab. That “seems like a bullish sign,” said Stifel analyst Paul Matteis.
In February, Biogen forecast weaker-than-expected earnings for 2021, amid mixed prognoses for its drugs. It predicted net income of $17 to $18.50 a share for this year, below the average analyst forecast of $25.09, according to Bloomberg.
It saw revenue at $10.45 billion to $10.75 billion, trailing analysts’ consensus estimate of $11.2 billion.